Cartesian Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
75
- Stock Symbol
-
RNAC
- Investments
-
1
- Share Price
-
$6.34
- (As of Friday Closing)
Cartesian Therapeutics General Information
Description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Contact Information
Website
www.cartesiantherapeutics.comCorporate Office
- 7495 New Horizon Way
- Frederick, MD
- United States
Corporate Office
- 7495 New Horizon Way
- Frederick, MD
- United States
Cartesian Therapeutics Timeline
Cartesian Therapeutics Stock Performance
As of 13-Nov-2026, Cartesian Therapeutics’s stock price is $6.34. Its current market cap is $194M with 30.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.34 | $6.36 | $5.60 - $11.00 | $194M | 30.5M | 137K | -$4.78 |
Cartesian Therapeutics Financials Summary
As of 30-Sep-2026, Cartesian Therapeutics has a trailing 12-month revenue of $2M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 134,388 | 56,705 | 250,634 | 42,511 |
| Revenue | 1,997 | 2,397 | 38,275 | 26,004 |
| EBITDA | (135,625) | (143,674) | (83,323) | (239,998) |
| Net Income | (127,461) | (130,302) | (77,424) | (219,710) |
| Total Assets | 294,305 | 296,411 | 435,023 | 305,050 |
| Total Debt | 60,336 | 12,676 | 13,984 | 10,955 |
Cartesian Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cartesian Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Cartesian Therapeutics Comparisons
Industry
Financing
Details
Cartesian Therapeutics Competitors (11)
One of Cartesian Therapeutics’s 11 competitors is Vedanta Biosciences, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| ImStem Biotechnology | Formerly VC-backed | Farmington, CT | ||||
| Collaborative Medicinal Development | Venture Capital-Backed | Mill Valley, CA | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Vitruvian Biomedical | Angel-Backed | Addison, TX |
Cartesian Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cartesian Therapeutics Patents
Cartesian Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024229370-A1 | Compositions and methods for treating gvhd | Inactive | 03-May-2023 | ||
| WO-2024229350-A1 | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes | Inactive | 03-May-2023 | ||
| WO-2024229380-A1 | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases | Inactive | 03-May-2023 | ||
| WO-2024229432-A1 | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance | Inactive | 03-May-2023 | ||
| WO-2024197098-A2 | Local conditioning of lymph nodes with diffusion-limited particles for in vivo car therapy | Inactive | 20-Mar-2023 | C12N15/88 |
Cartesian Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cartesian Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cartesian Therapeutics Acquisitions (1)
Cartesian Therapeutics’s most recent deal was a Merger/Acquisition with Selecta Biosciences. The deal was made on 13-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Selecta Biosciences | 13-Nov-2023 | Merger/Acquisition | Drug Discovery |
Cartesian Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.11 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Cartesian Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Selecta Biosciences | Watertown, MA | 2008 |
Cartesian Therapeutics FAQs
-
When was Cartesian Therapeutics founded?
Cartesian Therapeutics was founded in 2016.
-
Where is Cartesian Therapeutics headquartered?
Cartesian Therapeutics is headquartered in Frederick, MD.
-
What is the size of Cartesian Therapeutics?
Cartesian Therapeutics has 75 total employees.
-
What industry is Cartesian Therapeutics in?
Cartesian Therapeutics’s primary industry is Drug Discovery.
-
Is Cartesian Therapeutics a private or public company?
Cartesian Therapeutics is a Public company.
-
What is Cartesian Therapeutics’s stock symbol?
The ticker symbol for Cartesian Therapeutics is RNAC.
-
What is the current stock price of Cartesian Therapeutics?
As of 13-Nov-2026 the stock price of Cartesian Therapeutics is $6.34.
-
What is the current market cap of Cartesian Therapeutics?
The current market capitalization of Cartesian Therapeutics is $194M.
-
What is Cartesian Therapeutics’s current revenue?
The trailing twelve month revenue for Cartesian Therapeutics is $2M.
-
Who are Cartesian Therapeutics’s competitors?
Vedanta Biosciences, ImStem Biotechnology, Collaborative Medicinal Development, AnTolRx, and Vitruvian Biomedical are some of the 11 competitors of Cartesian Therapeutics.
-
What is Cartesian Therapeutics’s annual earnings per share (EPS)?
Cartesian Therapeutics’s EPS for 12 months was -$4.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
